Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 692549, 7 pages
http://dx.doi.org/10.1155/2013/692549
Research Article

Fucoidan Inhibits the Growth of Hepatocellular Carcinoma Independent of Angiogenesis

1Zhong-Shan-Men In-Patient Department, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, He-Xi District, Tianjin 300060, China
2Department of Oncology, Shandong Provincial Chest Hospital, Jinan 250013, China

Received 15 November 2012; Revised 24 March 2013; Accepted 22 April 2013

Academic Editor: Hong Q. Zhang

Copyright © 2013 Cong Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Czubayko, E. D. E. Liaudet-Coopman, A. Aigner, A. T. Tuveson, G. J. Berchem, and A. Wellstein, “A secreted FGF-binding protein can serve as the angiogenic switch in human cancer,” Nature Medicine, vol. 3, no. 10, pp. 1137–1140, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Carmeliet, “Angiogenesis in life, disease and medicine,” Nature, vol. 438, no. 7070, pp. 932–936, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Sasisekharan, S. Ernst, and G. Venkataraman, “On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans,” Angiogenesis, vol. 1, no. 1, pp. 45–54, 1997. View at Google Scholar · View at Scopus
  4. I. Vlodavsky, H. Q. Miao, B. Medalion, P. Danagher, and D. Ron, “Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor,” Cancer and Metastasis Reviews, vol. 15, no. 2, pp. 177–186, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. O. Goldshmidt, E. Zcharia, R. Abramovitch et al., “Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 15, pp. 10031–10036, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Ishai-Michaeli, A. Eldor, and I. Vlodavsky, “Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix,” Cell Regulation, vol. 1, no. 11, pp. 833–842, 1990. View at Google Scholar · View at Scopus
  7. I. Vlodavsky, N. Ilan, A. Naggi, and B. Casu, “Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate,” Current Pharmaceutical Design, vol. 13, no. 20, pp. 2057–2073, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Grose and C. Dickson, “Fibroblast growth factor signaling in tumorigenesis,” Cytokine and Growth Factor Reviews, vol. 16, no. 2, pp. 179–186, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. N. J. Harmer, “Insights into the role of heparan sulphate in fibroblast growth factor signalling,” Biochemical Society Transactions, vol. 34, no. 3, pp. 442–445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Mohammadi, S. K. Olsen, and O. A. Ibrahimi, “Structural basis for fibroblast growth factor receptor activation,” Cytokine and Growth Factor Reviews, vol. 16, no. 2, pp. 107–137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. C. Rapraeger, A. Krufka, and B. B. Olwin, “Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation,” Science, vol. 252, no. 5013, pp. 1705–1708, 1991. View at Google Scholar · View at Scopus
  12. N. S. Gandhi and R. L. Mancera, “Heparin/heparan sulphate-based drugs,” Drug Discovery Today, vol. 15, no. 23-24, pp. 1058–1069, 2010. View at Publisher · View at Google Scholar
  13. M. Rusnati and M. Presta, “Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies,” Current Pharmaceutical Design, vol. 13, no. 20, pp. 2025–2044, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. E. A. McKenzie, “Heparanase: a target for drug discovery in cancer and inflammation,” British Journal of Pharmacology, vol. 151, no. 1, pp. 1–14, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. X. Z. Wu, “New strategy of antiangiogenic therapy for hepatocellular carcinoma,” Neoplasma, vol. 55, no. 6, pp. 472–481, 2008. View at Google Scholar · View at Scopus
  16. C. R. Parish, C. Freeman, K. J. Brown, D. J. Francis, and W. B. Cowden, “Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity,” Cancer Research, vol. 59, no. 14, pp. 3433–3441, 1999. View at Google Scholar · View at Scopus
  17. M. Basche, D. L. Gustafson, S. N. Holden et al., “A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors,” Clinical Cancer Research, vol. 12, no. 18, pp. 5471–5480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Ferro, K. Dredge, L. Liu et al., “PI-88 and novel heparan sulfate mimetics inhibit angiogenesis,” Seminars in Thrombosis and Hemostasis, vol. 33, no. 5, pp. 557–568, 2007. View at Publisher · View at Google Scholar
  19. S. X. Zhang, C. Zhu, D. Chen et al., “Gekko sulfated glycopeptide inhibits angiogenesis by targeting basic fibroblast growth factor in hepatocellular carcinoma,” Journal of Biological Chemistry, vol. 287, pp. 13206–13215, 2012. View at Publisher · View at Google Scholar
  20. D. Chen, W. J. Yao, X. L. Zhang et al., “Effects of Gekko sulfated polysaccharide-protein complex on human hepatoma SMMC-7721 cells: inhibition of proliferation and migration,” Journal of Ethnopharmacology, vol. 127, no. 3, pp. 702–708, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Z. Wu, D. Chen, and G. R. Xie, “Effects of Gekko sulfated polysaccharide on the proliferation and differentiation of hepatic cancer cell line,” Cell Biology International, vol. 30, no. 8, pp. 659–664, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Z. Wu, D. Chen, and X. Q. Han, “Anti-migration effects of Gekko sulfated glycopeptide on human hepatoma SMMC-7721 cells,” Molecules, vol. 16, no. 6, pp. 4958–4970, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Chen, X. Zhang, Y. Du et al., “Effects of Gekko sulfated polysaccharide-protein complex on the defective biorheological characters of dendritic cells under tumor microenvironment,” Cell Biochemistry and Biophysics, vol. 62, no. 1, pp. 193–201, 2012. View at Publisher · View at Google Scholar
  24. X. Z. Wu, S. X. Zhang, C. Zhu, and D. Chen, “Effects of sulfated polysaccharide exctracted from Prunella vulgaris on endothelial cells,” Journal of Medicinal Plants Research, vol. 5, no. 17, pp. 4218–4223, 2011. View at Google Scholar
  25. L. Liu, M. Heinrich, S. Myers et al., “Towards a better understanding of medicinal uses of the brown seaweed Sargassum in Traditional Chinese medicine: a phytochemical and pharmacological review,” Journal of Ethnopharmacology, vol. 142, no. 3, pp. 591–619, 2012. View at Publisher · View at Google Scholar
  26. Y. Yamasaki, M. Yamasaki, H. Tachibana et al., “Important role of β1-integrin in fucoidan-induced apoptosis via caspase-8 activation,” Bioscience, Biotechnology, and Biochemistry, vol. 76, no. 6, pp. 1163–1168, 2012. View at Google Scholar
  27. H. S. Park, G. Y. Kim, T. J. Nam et al., “Antiproliferative activity of fucoidan was associated with the induction of apoptosis and autophagy in AGS human gastric cancer cells,” Journal of Food Science, vol. 76, no. 3, pp. T77–T83, 2011. View at Publisher · View at Google Scholar
  28. T. Nagamine, K. Hayakawa, T. Kusakabe et al., “Inhibitory effect of fucoidan on huh7 hepatoma cells through downregulation of CXCL12,” Nutrition and Cancer, vol. 61, no. 3, pp. 340–347, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. T. Ale, H. Maruyama, H. Tamauchi, J. D. Mikkelsen, and A. S. Meyer, “Fucoidan from Sargassum sp. and Fucus vesiculosus reduces cell viability of lung carcinoma and melanoma cells in vitro and activates natural killer cells in mice in vivo,” International Journal of Biological Macromolecules, vol. 49, no. 3, pp. 331–336, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Yang, C. Ma, J. Sun et al., “Fucoidan stimulation induces a functional maturation of human monocyte-derived dendritic cells,” International Immunopharmacology, vol. 8, no. 13-14, pp. 1754–1760, 2008. View at Publisher · View at Google Scholar
  31. Y. Hu, S. C. Cheng, K. T. Chan et al., “Fucoidin enhances dendritic cell-mediated T-cell cytotoxicity against NY-ESO-1 expressing human cancer cells,” Biochemical and Biophysical Research Communications, vol. 392, no. 3, pp. 329–334, 2010. View at Publisher · View at Google Scholar
  32. Y. Lv, Q. Song, Q. Shao et al., “Comparison of the effects of marchantin C and fucoidan on sFlt-1 and angiogenesis in glioma microenvironment,” Journal of Pharmacy and Pharmacology, vol. 64, no. 4, pp. 604–609, 2012. View at Publisher · View at Google Scholar
  33. A. Beenken and M. Mohammadi, “The FGF family: biology, pathophysiology and therapy,” Nature Reviews Drug Discovery, vol. 8, no. 3, pp. 235–253, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. R. K. Jain, D. G. Duda, C. G. Willett et al., “Sorensen AG: biomarkers of response and resistance to antiangiogenic therapy,” Nature Reviews Clinical Oncology, vol. 6, pp. 327–338, 2009. View at Publisher · View at Google Scholar
  35. P. Mitra, A. De, M. F. Ethier et al., “Loss of chemokine SDF-1α-mediated CXCR4 signalling and receptor internalization in human hepatoma cell line HepG2,” Cellular Signalling, vol. 13, no. 5, pp. 311–319, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Sutton, V. Friand, S. Brulé-Donneger et al., “Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion,” Molecular Cancer Research, vol. 5, no. 1, pp. 21–33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. C. J. Scotton, J. L. Wilson, K. Scott et al., “Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer,” Cancer Research, vol. 62, no. 20, pp. 5930–5938, 2002. View at Google Scholar · View at Scopus
  38. P. Mavier, N. Martin, D. Couchie, A. M. Preaux, Y. Laperche, and E. S. Zafrani, “Expression of stromal cell-derived factor-1 and of its receptor CXCR4 in liver regeneration from oval cells in rat,” The American Journal of Pathology, vol. 165, no. 6, pp. 1969–1977, 2004. View at Publisher · View at Google Scholar